The following neurotransmitter/neuropeptide receptor blockers were used: CCK-A receptor antagonist devazepide (2 mg kg–1 in 5% DMSO PBS; Sigma)14 (link),53 (link), cocktail of the ionotropic glutamate receptor antagonist KA (150 μg kg–1 in PBS, stock made in 1 M NaOH then diluted, pH 7.4; Sigma)14 (link),54 (link) and the metabotropic glutamate receptor antagonist AP3 (1 mg kg–1 in PBS, stock made in 1 M NaOH diluted, pH 7.4; Sigma)14 (link),55 (link) and non-selective P2-purinoreceptor antagonist PPADs (25 mg kg–1 in PBS; Sigma)32 (link),56 (link)–58 (link). Following recording of a preinhibitor response, one inhibitor was delivered over 1 min (devazepide and PPADs were delivered at 10 μl g–1; the KA/AP3 cocktail was delivered at 20 μl g–1). Infusion of the selected sugar ligand was repeated for postinhibitor recording after an incubation period of 5–8 min for devazepide and 3–5 min for KA/AP3 and PPADs.
Free full text: Click here